Codexis, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Segment, Geographical and Other Revenue Information (Tables)

Segment, Geographical and Other Revenue Information (Tables)

3 Months Ended

Mar. 31, 2020

The following table provides financial information by our reportable business segments along with a reconciliation to consolidated loss before income taxes (in thousands):


	Three months ended March 31, 2020										Three months ended March 31, 2019
	Performance Enzymes		Novel Biotherapeutics		Total		Performance Enzymes		Novel Biotherapeutics		Total
Revenues:
Product revenue	$	5,100	$	—	$	5,100	$	7,988	$	—	$	7,988
Research and development revenue	5,774		3,796		9,570		2,099		5,496		7,595
Total revenues	10,874		3,796		14,670		10,087		5,496		15,583
Costs and operating expenses:
Cost of product revenue	2,541		—		2,541		4,391		—		4,391
Research and development⁽¹⁾	5,696		4,925		10,621		4,442		3,317		7,759
Selling, general and administrative⁽¹⁾	2,345		591		2,936		2,101		517		2,618
Total segment costs and operating expenses	10,582		5,516		16,098		10,934		3,834		14,768
Income (loss) from operations	$	292	$	(1,720)	(1,428)		$	(847)	$	1,662	815
Corporate costs ⁽²⁾					(5,727)						(5,575)
Depreciation and amortization					(492)						(373)
Loss before income taxes					$	(7,647)					$	(5,133)

⁽¹⁾Research and development expenses and Selling, general and administrative expenses exclude depreciation and amortization of finance leases.

⁽²⁾Corporate costs include unallocated selling, general and administrative expense, interest income, and other income and expenses.

The following table provides stock-based compensation expense included in loss from operations (in thousands):


	Three months ended March 31,
	2020														2019
	Performance Enzymes		Novel Biotherapeutics		Corporate cost		Total		Performance Enzymes		Novel Biotherapeutics		Corporate cost		Total
Stock-based compensation	$	756	$	241	$	1,172	$	2,169	$	636	$	141	$	1,286	$	2,063

Schedule of customers that contributed 10% or more of total accounts receivable

Customers that each accounted for 10% or more of our total revenues were as follows:


	Three Months Ended March 31,
	2020		2019
Customer A	24	%	41	%
Customer B	19	%	—	%
Customer C	15	%	—	%
Customer D	11	%	35	%

Customers that each accounted for 10% or more of accounts receivable had balances as of the periods presented as follows:


	Percentage of Accounts Receivables as of
	March 31, 2020		December 31, 2019
Customer A	47	%	38	%
Customer D	—	%	10	%

* Percentage was less than 10%

Schedule of revenues by geographical area

Geographic revenues are identified by the location of the customer and consist of the following (in thousands):


	Three Months Ended March 31,
	2020		2019
Revenues
Americas	$	5,225	$	2,838
EMEA	5,971		7,726
APAC	3,474		5,019
Total revenues	$	14,670	$	15,583

Schedule of long-lived assets by geographical area

Identifiable long-lived assets by location was as follows (in thousands):


Long-lived assets	March 31, 2020		December 31, 2019
United States	$	6,647	$	6,282

Schedule of intangible assets and goodwill

Identifiable goodwill was as follows (in thousands):


	March 31, 2020										December 31, 2019
	Performance Enzymes		Novel Biotherapeutics		Total		Performance Enzymes		Novel Biotherapeutics		Total
Goodwill	$	2,463	$	778	$	3,241	$	2,463	$	778	$	3,241